azn201402106k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of February 2014
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 8 February 2014, Bruce Burlington, a Director of the Company notified us that, on 7 February 2014, he purchased 500 AstraZeneca American Depositary Shares (ADSs) at a price of $62.92 per ADS.
One AstraZeneca ADS equals one AstraZeneca PLC Ordinary Share of $0.25.
Following this purchase, Mr Burlington has a total interest in 2,053 AstraZeneca shares.
A C N Kemp
Company Secretary
10 February 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
|
Date: 10 February 2014
|
By: /s/ Adrian Kemp
|
| |
Name: Adrian Kemp
|
| |
Title: Company Secretary
|